NW Bio Partners with UK NHS Blood and Transplant to Scale DCVax-L Production
NWBO is trading near its 52-week low of $0.138 (7.2% above the low).
Summary
Northwest Biotherapeutics announced a collaboration with the UK National Health Service Blood and Transplant to support production of its DCVax-L brain cancer treatment. This is a significant operational step for a company with only $595K in cash and a going concern warning as of Q2. The partnership leverages NHS infrastructure, potentially reducing manufacturing bottlenecks and validating the therapy's path toward commercialization. It follows the MHRA's confirmation in July that the DCVax-L application remains under review. The collaboration could improve supply readiness ahead of a potential regulatory decision, though no financial terms were disclosed.
At the time of this announcement, NWBO was trading at $0.15 on OTC in the Life Sciences sector, with a market capitalization of approximately $252.4M. The 52-week trading range was $0.14 to $0.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.